AusperBio has successfully completed a USD 73 million Series B financing.

The round was led by HanKang Capital, with participation from Sherpa Capital, CDH Investments, and a strategic investor, as well as continued participation from existing investors Qiming Venture Partners, InnoPinnacle Fund, and YuanBio Venture Capital.

This financing followed the company's Series A round completed in July this year, demonstrating continued investor confidence in its proprietary platform and strategic direction.

The proceeds will fund the continued Phase 2 development of AHB-137, AusperBio's lead investigational therapy, supporting both clinical studies in China and global trials, as well as the development of commercial-scale manufacturing processes. The funding will also facilitate the expansion of the company's therapeutic pipeline and operational capabilities to drive sustained growth.

Dr. Guofeng Cheng, co-founder and CEO of AusperBio, stated, " We are honored by our investors' confidence and support. This milestone financing recognizes our scientific and clinical accomplishments to date and enables us to accelerate our clinical programs and move closer to delivering a functional cure for CHB patients in need."

Dr. Chris Yang, co-founder and CSO, added, "AHB-137 continues to attract attention from the scientific and clinical communities, particularly after the late-breaking oral presentation at the recent AASLD conference. The promising clinical data further validates our Med-Oligo™ platform, strengthening our development of groundbreaking targeted oligonucleotide therapies for CHB and other serious chronic diseases."

AusperBio is committed to delivering patient-centered innovations, aiming to alleviate the global health burden of CHB and transform treatment paradigms for this serious chronic disease.